Clinical-stage biopharmaceutical company, Immatics Biotechnologies, has entered into a research collaboration and licence agreement with international biotech company, Genmab, to develop next generation bispecific cancer immunotherapies.
More From BioPortfolio on "Biopharma enters into research collaboration and licence agreement with biotech"